EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Director Sells $116,947.50 in Stock

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Director David R. Guyer sold 11,625 shares of the firm’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $10.06, for a total value of $116,947.50. Following the sale, the director now directly owns 1,850 shares of the company’s stock, valued at approximately $18,611. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

EyePoint Pharmaceuticals Trading Down 8.5 %

NASDAQ:EYPT opened at $8.85 on Friday. The stock has a fifty day moving average price of $9.87 and a 200 day moving average price of $18.28. EyePoint Pharmaceuticals, Inc. has a 12-month low of $5.67 and a 12-month high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.21). The company had revenue of $11.68 million during the quarter, compared to analysts’ expectations of $12.50 million. EyePoint Pharmaceuticals had a negative net margin of 157.77% and a negative return on equity of 49.94%. As a group, sell-side analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on EYPT shares. Mizuho lowered their price target on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Cantor Fitzgerald restated an “overweight” rating on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 20th. JPMorgan Chase & Co. lowered their price target on EyePoint Pharmaceuticals from $35.00 to $32.00 and set an “overweight” rating for the company in a research report on Tuesday, June 4th. Robert W. Baird lowered their price target on EyePoint Pharmaceuticals from $46.00 to $38.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $33.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EYPT. Franklin Resources Inc. lifted its holdings in EyePoint Pharmaceuticals by 11.8% during the 4th quarter. Franklin Resources Inc. now owns 4,640,651 shares of the company’s stock worth $107,245,000 after buying an additional 488,206 shares during the last quarter. Vanguard Group Inc. lifted its holdings in EyePoint Pharmaceuticals by 17.8% during the 1st quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock worth $49,530,000 after buying an additional 362,168 shares during the last quarter. Jennison Associates LLC purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter worth about $24,641,000. RA Capital Management L.P. purchased a new stake in EyePoint Pharmaceuticals during the 1st quarter worth about $19,401,000. Finally, Federated Hermes Inc. lifted its holdings in EyePoint Pharmaceuticals by 194.0% during the 4th quarter. Federated Hermes Inc. now owns 674,824 shares of the company’s stock worth $15,595,000 after buying an additional 445,289 shares during the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.